Fig. 7

UroA/UAS03 utilize Nrf2 pathways to mitigate colitis. a–e Colitis was induced using TNBS in C57BL/6 (WT) and Nrf2^−/− mice (n = 4–5/group 7–8 week old age). Mice were treated with Veh or UroA/UAS03 (20 mg/kg bodyweight) every 12 h post TNBS administration ending at 72 h. Representative data from two independent experiments is shown. a TNBS-induced colitis experimental design and treatment regimen. b Percent body weight loss (No TNBS- Solid black line; Veh + TNBS- Solid red line; UroA + TNBS- Solid blue line; UAS03 + TNBS- Solid purple line), c representative colon images, d colon lengths, e gut permeability, f serum levels of IL-6 and TNF-α were determined. Statistical analysis was performed (unpaired t-test) using Graphpad Prism software. Error bars, ±SEM ***p < 0.001; **p < 0.01 *p < 0.05. Source Data are provided as a Source Data File